IGF-1 LR3 Reconstitution Chart (Every Vial Size)

Overview of IGF-1 LR3 Reconstitution in Laboratory Settings

Recombinant Long R3 Insulin-like Growth Factor-1 (IGF-1 LR3) is a 83-amino acid synthetic analogue of human IGF-1 engineered specifically to reduce binding affinity to insulin-like growth factor binding proteins (IGFBPs). In preclinical and cellular models, this structural modification increases the bioavailable half-life of the peptide in culture media and tissue models. To execute reproducible bioassays, researchers must consistently calculate final working concentrations based on lyophilizate mass and solvent addition.

When receiving lyophilized cake in sealed borosilicate vials, proper reconstitution requires calculating the final concentration (mg/mL or mcg/mL) and understanding the per-graduation content for volumetric delivery equipment such as micro-pipettes or insulin-style laboratory syringes. Utilizing an accurate igf-1 lr3 reconstitution chart eliminates variance between experimental replicates and ensures exact molar exposure in culture or animal models.

PX1 Research supplies analytical-grade reagents for laboratory research use only. Every batch of our high-purity IGF-1 LR3 is processed under strict quality controls and accompanied by analytical verification to ensure predictable solubility and concentration math.

Master IGF-1 LR3 Reconstitution Chart

The following master reference table provides exact concentrations resulting from combining common IGF-1 LR3 vial masses (100 mcg, 1 mg, and 2 mg) with standardized volumes of laboratory diluents (0.5 mL to 2.5 mL). All values are expressed in both mass concentration (mg/mL or mcg/mL) and mass per 0.1 mL (10 Units on a standard U-100 syringe barrel).

| Vial Mass | Diluent Volume | Final Concentration (mg/mL) | Final Concentration (mcg/mL) | Mass per 0.1 mL (100 µL) | |---|---|---|---|---| | 100 mcg (0.1 mg) | 0.5 mL | 0.20 mg/mL | 200 mcg/mL | 20 mcg | | 100 mcg (0.1 mg) | 1.0 mL | 0.10 mg/mL | 100 mcg/mL | 10 mcg | | 100 mcg (0.1 mg) | 2.0 mL | 0.05 mg/mL | 50 mcg/mL | 5 mcg | | 1 mg (1,000 mcg) | 1.0 mL | 1.00 mg/mL | 1,000 mcg/mL | 100 mcg | | 1 mg (1,000 mcg) | 2.0 mL | 0.50 mg/mL | 500 mcg/mL | 50 mcg | | 1 mg (1,000 mcg) | 2.5 mL | 0.40 mg/mL | 400 mcg/mL | 40 mcg | | 2 mg (2,000 mcg) | 1.0 mL | 2.00 mg/mL | 2,000 mcg/mL | 200 mcg | | 2 mg (2,000 mcg) | 2.0 mL | 1.00 mg/mL | 1,000 mcg/mL | 100 mcg | | 2 mg (2,000 mcg) | 2.5 mL | 0.80 mg/mL | 800 mcg/mL | 80 mcg |

For custom diluent volumes or non-standard vial masses not listed in this master reference table, researchers can utilize our interactive reconstitution calculator to immediately compute precise working concentrations.

Mathematical Formula for Peptide Reconstitution

Calculating concentration after reconstituting a lyophilized peptide requires a straightforward mass-balance equation. Understanding this underlying arithmetic ensures that laboratory personnel can verify working concentrations regardless of custom diluent ratios.

The fundamental equation for liquid concentration is: Concentration (C) = Mass (M) / Volume (V). When working with microgram-scale research compounds, converting units to a uniform scale prevents errors. The primary conversions are: 1 milligram (mg) = 1,000 micrograms (mcg), and 1 milliliter (mL) = 1,000 microliters (µL).

To determine the specific mass delivered per fractional volumetric increment (e.g., per 0.01 mL or per U-100 syringe unit): Target Mass per Increment = (Total Vial Mass / Total Diluent Volume) × Increment Volume. For example, if 1 mg (1,000 mcg) is dissolved in 2.0 mL (2,000 µL), the resulting concentration is 0.5 mcg/µL. Multiplying by a 100 µL sampling volume yields exactly 50 mcg of target peptide.

Worked Calculation Example 1: 1 mg Vial Reconstitution

Consider a standard experimental protocol calling for a target dilution from a 1 mg (1,000 mcg) vial of IGF-1 LR3 using 2.0 mL of sterile diluent. Step 1: Identify total mass. M = 1,000 mcg. Step 2: Identify total diluent volume. V = 2.0 mL.

Step 3: Calculate base concentration. C = 1,000 mcg / 2.0 mL = 500 mcg/mL (or 0.5 mg/mL). Step 4: Calculate content per 0.01 mL graduation (1 Unit on a U-100 volumetric syringe). Content per Unit = 500 mcg/mL / 100 units/mL = 5 mcg per Unit.

If a cell culture assay requires a 25 mcg aliquot added to a reaction well, the researcher would draw exactly 5 units (0.05 mL) of reconstituted solution using a calibrated lab micro-pipette or volumetric syringe.

Worked Calculation Example 2: 100 mcg Micro-Vial Reconstitution

In assays requiring low overall peptide mass or limited initial reconstitution, a micro-vial containing 100 mcg (0.1 mg) of lyophilized IGF-1 LR3 may be preferred to prevent repeated freeze-thaw degradation of unused reconstituted liquid. Step 1: Identify total mass. M = 100 mcg. Step 2: Choose diluent volume. V = 1.0 mL.

Step 3: Calculate base concentration. C = 100 mcg / 1.0 mL = 100 mcg/mL (0.1 mg/mL). Step 4: Calculate content per 0.1 mL (10 units). Content per 0.1 mL = 100 mcg/mL × 0.1 mL = 10 mcg.

If a preclinical tissue incubation model requires 2 mcg of active peptide per treatment group, the volumetric delivery volume is calculated as: Volume = Target Mass / Concentration = 2 mcg / (100 mcg/mL) = 0.02 mL (20 µL or 2 units).

Selection of Laboratory Diluents and Solvent Compatibility

Selecting the correct diluent is critical to maintain protein stability and prevent aggregation during storage. Recombinant IGF-1 LR3 exhibits distinct solubility profiles depending on pH and ionic strength.

For short-term or immediate assay execution, sterile 0.9% sodium chloride or phosphate-buffered saline (PBS) may be utilized. However, for extended storage after reconstitution, bacteriostatic water solvent (containing 0.9% benzyl alcohol) is typically employed to inhibit micro-organism growth. IGF-1 LR3 is particularly stable in slightly acidic conditions; many specialized cell culture protocols recommend initial reconstitution in 10 mM to 100 mM acetic acid (pH 2.5–3.0) to form a high-concentration stock solution (e.g., 1 mg/mL) before further dilution into culture media containing carrier proteins such as 0.1% Bovine Serum Albumin (BSA).

Avoid high-speed vortexing during dissolution. Lyophilized peptide cakes should be reconstituted by gently swirling the diluent along the inner glass wall of the borosilicate vial to minimize shear stress and protein denaturation.

Comparative Analysis: IGF-1 LR3 vs Native IGF-1 vs IGF-1 DES

When designing preclinical growth factor assays, researchers evaluate multiple structural variants within the insulin-like growth factor superfamily. Each variant exhibits distinct binding kinetics, receptor affinity, and stability profiles.

Native IGF-1 is a 70-amino acid endogenous protein that binds strongly to soluble IGF binding proteins (IGFBPs), which modulate its bioavailability in vivo and in vitro. Long R3 IGF-1 (IGF-1 LR3) incorporates an 13-amino acid N-terminal extension and a substitution of Glutamic acid for Arginine at position 3. This alteration drastically reduces affinity for IGFBPs while retaining high affinity for the IGF-1 receptor (IGF-1R), resulting in significantly extended biological activity in culture media. In contrast, the IGF-1 DES research compound lacks the first three N-terminal amino acids (Gly-Pro-Glu), giving it enhanced potency in tissues rich in IGFBPs but a shorter overall persistence profile.

Researchers reviewing our complete catalog of research peptides can compare kinetic specifications across these growth factors to select the exact analogue required for their experimental design.

Best Practices for Reconstitution, Handling, and Aliquoting

To maintain maximal biological activity of IGF-1 LR3 solutions, laboratory personnel should adhere to standardized molecular biology handling protocols:

1. Aseptic Technique: Reconstitution should always occur within a certified laminar flow hood or biosafety cabinet using sterile, pyrogen-free equipment. 2. Evacuate Vacuum: Lyophilized vials from PX1 Research are stoppered under vacuum or inert gas. Allow diluent to enter slowly along the glass wall rather than forcing direct high-pressure impact onto the lyophilized cake. 3. Complete Solubilization: Allow the vial to sit at room temperature for 2–5 minutes post-diluent introduction, followed by gentle inversion. Do not shake violently. 4. Aliquoting: To avoid repeated freeze-thaw cycles—which degrade tertiary protein structure—divide reconstituted stock solutions into single-use microcentrifuge tubes immediately. 5. Storage Temperature: Lyophilized IGF-1 LR3 is stable at -20°C to -80°C long term. Once reconstituted, stock solutions in acidified media with 0.1% BSA remain stable at 2°C to 8°C for up to 2–4 weeks, or at -80°C for up to 6–12 months.

Quality Verification: HPLC, Mass Spectrometry, and Endotoxin Standards at PX1

Inconsistent peptide purity or contamination with bacterial endotoxins can confound experimental results, alter cell viability assays, and compromise receptor binding kinetics. PX1 Research enforces rigorous batch-level analytical testing to guarantee research-grade standards.

Every production lot undergoes High-Performance Liquid Chromatography (HPLC) to verify chemical purity (>98%) and Mass Spectrometry (MS) to confirm exact molecular mass (9,111 Da for IGF-1 LR3). Furthermore, our compounds undergo Chromogenic LAL testing to confirm endotoxin levels fall below strict laboratory threshold standards (<0.01 EU/µg).

All analytical documentation is publicly available and verifiable via our lot-specific COA database. Laboratories procuring reagents through the PX1 wholesale research program receive comprehensive analytical support and batch documentation for audit compliance.